Anakinra

Adult: For the treatment of cryopyrin associated periodic syndromes (CAPS), including neonatal-onset multisystem inflammatory disease (NOMID), familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS): Initially, 1-2 mg/kg daily. Initial dose may be maintained in mild CAPS (FCAS and mild MWS). In severe CAPS (MWS and NOMID), dose may be adjusted in increments of 0.5-1 mg/kg after 1-2 months based on therapeutic response; usual maintenance dose is 3-4 mg/kg daily, may be adjusted up to a Max of 8 mg/kg daily. Doses may be administered once daily (preferred) or divided and administered bid. Treatment recommendations may vary among countries (refer to local or country-specific product guidelines).
Child: ≥8 months Patients weighing ≥10 kg: Same as adult dose.

Adult: For moderate to severely active cases when response to methotrexate or another DMARD alone has been inadequate: 100 mg once daily given at approx same time each day. Dose may be given alone or in combination with methotrexate or other DMARDs (excluding tumour necrosis factor [TNF] inhibitors). Treatment recommendations may vary among countries (refer to local or country-specific product guidelines).

Adult: Initially, 1-2 mg/kg daily. Dose may be adjusted in increments of 0.5-1 mg/kg as necessary, up to a Max of 8 mg/kg daily. Treatment recommendations may vary among countries (refer to local or country-specific product guidelines).

Adult: As monotherapy or in combination with other anti-inflammatory agents and DMARDs in patients with active systemic features of moderate to high disease activity or with continued disease activity after NSAIDs or corticosteroids treatment: Patients weighing <50 kg: Initially, 1-2 mg/kg daily; ≥50 kg: 100 mg daily. Evaluate clinical response after 1 month of therapy. Dosage and treatment recommendations may vary among countries (refer to local or country-specific product guidelines).
Child: ≥8 months As monotherapy or in combination with other anti-inflammatory agents and DMARDs in patients with active systemic features of moderate to high disease activity or with continued disease activity after NSAIDs or corticosteroids treatment: Patients weighing 10-49 kg: Initially, 1-2 mg/kg daily; ≥50 kg: 100 mg daily. Dose may be adjusted up to 4 mg/kg daily if response is inadequate. Evaluate clinical response after 1 month of therapy. Dosage and treatment recommendations may vary among countries (refer to local or country-specific product guidelines).